Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Curr Oncol Rep. 2024 May;26(5):439-465. doi: 10.1007/s11912-024-01519-4. Epub 2024 Mar 28.
The purpose of this review is to discuss a wide variety of novel therapies recently studied or actively undergoing study in patients with glioblastoma. This review also discusses current and future strategies for improving clinical trial design in patients with glioblastoma to maximize efficacy in discovering effective treatments.
Over the years, there has been significant expansion in therapy modalities studied in patients with glioblastoma. These therapies include, but are not limited to, targeted molecular therapies, DNA repair pathway targeted therapies, immunotherapies, vaccine therapies, and surgically targeted radiotherapies. Glioblastoma is the most common malignant primary brain tumor in adults and unfortunately remains with poor overall survival following the current standard of care. Given the dismal prognosis, significant clinical and research efforts are ongoing with the goal of improving patient outcomes and enhancing quality and quantity of life utilizing a wide variety of novel therapies.
本文旨在讨论近年来在胶质母细胞瘤患者中研究或正在积极研究的各种新疗法。本文还讨论了目前和未来改善胶质母细胞瘤患者临床试验设计的策略,以最大限度地提高发现有效治疗方法的疗效。
多年来,胶质母细胞瘤患者的治疗方式有了显著的扩展。这些疗法包括但不限于靶向分子疗法、DNA 修复途径靶向疗法、免疫疗法、疫苗疗法和手术靶向放疗。胶质母细胞瘤是成人中最常见的恶性原发性脑肿瘤,不幸的是,在目前的标准治疗下,总体生存率仍然很差。鉴于预后不佳,正在进行大量的临床和研究工作,目标是利用各种新疗法改善患者的预后,提高生活质量和数量。